```html

Tongue Tuberculosis (Oral Tuberculosis)

Overview

Tongue tuberculosis (TB) is a rare form of extrapulmonary tuberculosis that involves the mucosal surface of the tongue. It is caused by Mycobacterium tuberculosis, the same bacterium that typically infects the lungs. While pulmonary TB accounts for the vast majority of cases worldwide, oral TB—including tongue involvement—represents less than 0.1% of all TB cases.<sup>1</sup>

Who it affects: The condition can affect anyone infected with TB, but it is most commonly reported in adults aged 30‑60 years, especially those with compromised immunity (e.g., HIV infection, diabetes, malnutrition) or a history of pulmonary TB.<sup>2</sup>

Prevalence: According to the World Health Organization (WHO), there were an estimated 10 million new TB cases globally in 2023, but only a handful (< 1 % of extrapulmonary TB) involve the oral cavity. In the United States, the CDC reports fewer than 200 oral‑TB cases annually.<sup>3</sup>

Symptoms

Because the tongue is a muscular organ, TB can mimic common oral conditions. The most frequent symptoms include:

• Painless or painful ulcer – often a single, well‑defined ulcer with irregular margins that may bleed easily.
• Surface nodules or plaques – raised, creamy‑white or erythematous lesions that can coalesce.
• Swelling of the tongue – generalized or localized edema, sometimes causing difficulty speaking (dysarthria) or swallowing (dysphagia).
• Foul taste or odor – due to necrotic tissue or secondary bacterial infection.
• Weight loss – a systemic sign of TB infection.
• Fever, night sweats, and fatigue – typical constitutional TB symptoms that may accompany oral lesions.
• Bleeding – especially when the ulcer is scraped or during eating.

Symptoms often develop slowly over weeks to months, leading many patients to seek care only when lesions become painful or interfere with eating.

Causes and Risk Factors

Primary cause

Infection by Mycobacterium tuberculosis. The organism reaches the tongue through one of three pathways:

1. Direct inoculation – via contaminated sputum in patients with active pulmonary TB.
2. Hematogenous spread – dissemination through the bloodstream from a distant focus.
3. Lymphatic spread – extension from cervical lymph nodes or adjacent oral structures.

Risk factors

• Existing pulmonary or laryngeal TB (most common source of oral lesions).
• Immunosuppression (HIV/AIDS, organ transplantation, chemotherapy, long‑term corticosteroids).
• Chronic diseases such as diabetes mellitus or chronic kidney disease.
• Poor oral hygiene, tobacco use, or chronic irritation (e.g., from sharp teeth or ill‑fitting dentures).
• Malnutrition and low body‑mass index.
• Living or working in high‑TB‑burden settings (e.g., prisons, shelters, crowded urban areas).

Diagnosis

Diagnosing tongue TB requires a combination of clinical suspicion, laboratory testing, and imaging. Because the presentation can resemble aphthous ulcers, squamous cell carcinoma, or fungal infections, a definitive diagnosis is essential.

Step‑by‑step diagnostic approach

1. History & physical examination – Document TB exposure, pulmonary symptoms, immune status, and oral hygiene.
2. Biopsy of the lesion – The gold standard. Histopathology typically shows caseating granulomas with Langhans‑type giant cells.
3. Acid‑fast bacilli (AFB) staining – Ziehl‑Neelsen or Kinyoun stain on tissue sections; may demonstrate mycobacteria.
4. Culture – Mycobacterial culture on Lowenstein‑Jensen medium or liquid media (e.g., MGIT); takes 2‑8 weeks but confirms species and drug susceptibility.
5. Nucleic acid amplification tests (NAATs) – Rapid PCR‑based assays (e.g., GeneXpert MTB/RIF) can detect M. tuberculosis and rifampin resistance within hours.
6. Chest radiography or CT – To evaluate for concurrent pulmonary TB.
7. Blood tests – Complete blood count, erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP) for inflammation; HIV testing if risk factors present.

According to the CDC, a combination of histology + NAAT yields a diagnostic sensitivity of > 85 % for oral TB.<sup>4</sup>

Treatment Options

The treatment regimen mirrors that for pulmonary TB, following WHO and national guidelines.

Standard anti‑TB drug regimen

• Intensive phase (2 months) – Isoniazid (INH), Rifampin (RIF), Pyrazinamide (PZA), and Ethambutol (EMB) – often abbreviated as “HRZE”.
• Continuation phase (4–7 months) – Isoniazid + Rifampin (HR) for an additional 4 months, extended to 7 months if response is slow.

Drug dosages are weight‑based; therapy is usually administered daily (or 5 days/week under directly observed therapy, DOT). Adherence is critical—missed doses increase the risk of drug‑resistant TB.

Management of drug‑resistant disease

If rifampin resistance or multidrug‑resistant TB (MDR‑TB) is identified, second‑line agents (e.g., fluoroquinolones, linezolid, bedaquiline) are added per WHO MDR‑TB guidelines.<sup>5</sup>

Adjunctive measures

• Nutrition support – High‑protein, calorie‑dense diet; supplementation with vitamins A, D, and zinc to aid immune function.
• Oral hygiene – Gentle brushing with a soft toothbrush, saline mouth rinses, and avoidance of irritants (spicy foods, tobacco).
• Pain control – Topical anesthetics (lidocaine gel) or short courses of NSAIDs.
• Surgical debridement – Rarely required; may be considered for large necrotic lesions that impede nutrition.

Living with Tongue Tuberculosis

Successful treatment requires a blend of medical therapy, lifestyle adjustments, and psychosocial support.

Daily management tips

1. Medication adherence – Use pill organizers, set alarms, or enroll in a DOT program.
2. Hydration – Sip water or oral rehydration solutions frequently to keep the tongue moist.
3. Soft diet – Pureed foods, smoothies, and yoghurt reduce mechanical trauma to the ulcer.
4. Oral care routine – Brush after meals, rinse with 0.9 % saline or chlorhexidine (if not contraindicated).
5. Monitor side effects – Report visual changes (ethambutol), peripheral neuropathy (INH), or liver discomfort (INH, PZA, RIF).
6. Follow‑up appointments – Typically every 2 weeks during the intensive phase, then monthly.
7. Psychological support – Consider counseling or support groups, especially if stigma around TB is a concern.

Returning to work/school

Patients are usually non‑infectious after 2 weeks of effective therapy if sputum smears are negative. Discuss clearance with a healthcare provider and follow local public‑health guidelines.

Prevention

Preventing tongue TB is essentially the same as preventing any form of TB.

• Vaccination – BCG vaccine offers partial protection, especially against severe forms of TB in children.
• Infection control – Use of masks, adequate ventilation, and respiratory hygiene in high‑risk settings.
• Screening – Regular TB skin tests (TST) or interferon‑γ release assays (IGRA) for healthcare workers, close contacts of TB patients, and immunocompromised individuals.
• Prompt treatment of active pulmonary TB – Reduces the bacterial load that can seed the oral cavity.
• Oral health – Maintain good dental hygiene, treat chronic oral lesions, and avoid tobacco or excessive alcohol.

Complications

If left untreated, tongue TB can lead to serious sequelae:

• Extensive ulceration – May cause permanent scar tissue, affecting speech and swallowing.
• Secondary bacterial infection – Can progress to cellulitis or abscess formation.
• Spread to adjacent structures – Invasion of the floor of mouth, floor of the palate, or cervical lymph nodes.
• Systemic dissemination – Hematogenous spread to other organs (bones, meninges).
• Malignancy misdiagnosis – Chronic ulceration may be mistaken for squamous cell carcinoma, delaying appropriate therapy.

When to Seek Emergency Care

---

References:
1. World Health Organization. Global Tuberculosis Report 2023.
2. Sharma SK, et al. Extrapulmonary Tuberculosis: An Overview. Cureus. 2022;14(9).
3. Centers for Disease Control and Prevention. Tuberculosis Surveillance Data, 2023.
4. CDC. “Testing for Tuberculosis (TB) in the United States.” Updated 2022.
5. WHO. “Guidelines for the Treatment of Drug‑Resistant Tuberculosis.” 2023.

```